Table 2 Summary of adverse effects on the trial
Adverse events | Total, n (%) | Grade 1 and 2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|---|
Related to WT1 vaccine (all with Montanide) | |||||
 Injection sites ulceration | 1 (14%) |  | 1 |  |  |
 Injection sites reaction | 4 (57%) | 4 |  |  |  |
SAEs unrelated to WT1 vaccine | |||||
 Ascending myelitis due to infection | 1 (14%) |  |  |  | 1 |
 Hyperglycemia due to uncontrolled DM | 1 (14%) |  | 1 |  |  |
 Thrombocytopenia due to disease | 1 (14%) |  | 1 |  |  |
 Anemia due to disease | 1 (14%) |  | 1 |  |  |
 Depression | 1 (14%) |  |  | 1 |  |
 Upper respiratory infection (viral) | 3 (43%) | 3 |  |  |  |